ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 5722
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 


For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series


For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

About the episode

We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial (Medtronic Cardiovascular). This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis who had low surgical risk.

TAVR had consistent benefit at 3 years compared with surgery in terms of all-cause mortality and disabling stroke.


  1. What is the reasoning behind this trial?
  2. Please outline the patient population and study design.
  3. What are the main results?
  4. What are the implications of these findings for clinical practice?
  5. What further research is required?

Recorded on-site at ACC.23, New Orleans, 2023. 

Faculty Biographies

John Forrest

View full profile


You must be to comment. If you are not registered, you can register here.